TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03644004

Intervention type: OTHER
Intervention: frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.
Description: Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data.
Study: NCT01717027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
Study: NCT04028219

Intervention type: DIAGNOSTIC_TEST
Intervention: Online surveys
Description: Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
Study: NCT01746901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution + Placebo ALO-02 (intact)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intact ALO-02 60 mg/7.2 mg
Description: Placebo solution + ALO-02 60 mg/7.2 mg (intact)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crushed ALO-02 60 mg/7.2 mg
Description: crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crushed oxycodone IR 60 mg
Description: crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crushed ALO-02 40 mg/4.8 mg
Description: crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crushed oxycodone IR 40 mg
Description: crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
Study: NCT04063007

Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic diet
Description: The patients follow the ordinary treatment protocol for ketogenic diet
Study: NCT01351181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet
Description: Advice Leaflet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Advice
Description: Leaflet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Normal Care
Description: Normal Care
Study: NCT00664625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Once Daily, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Once Daily, Single Dose
Study: NCT02824341

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI
Study: NCT00803569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine
Description: The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: The GM-CSF sargramostim is administered at a dose of 100 μg SC.
Study: NCT00495352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hihg-doseNRT, Low-dose NRT, bupropion
Study: NCT00694941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506PO
Description: 1200mg QD / 5 years
Study: NCT00649038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin HCT® Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed
Study: NCT04423302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-63 3 intakes per day
Description: 5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3 intakes per day
Description: Placebo. Eight capsules per day to consume orally in three intakes (3 in the morning, 2 at lunch and 3 at dinner)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-63 2 intakes per day
Description: 5-g dose of TOTUM-63 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes (4 in the morning and 4 at dinner)
Study: NCT00927953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGAWN1
Description: Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - normal saline
Description: Normal Saline intravenous, volume same as active comparator, one dose at Day 0
Study: NCT00825487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 621
Description: Treatment will be initiated at a dose level of 10 mg/m\^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m\^2 and higher (cohort 8 and above).
Study: NCT01839955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinacrine dihydrochloride - Escalation dose
Description: Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 \[starting dose\]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinacrine dihydrochloride - Extension dose
Description: Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
Study: NCT01921309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trinity CoC Total Hip System
Description: total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trinity Ceramic-on-Poly THR
Description: total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
Study: NCT03946475

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label.
Study: NCT00675272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Description: hydrocortisone 50mg iv. every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride every 6 hours iv
Study: NCT00589199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement and use of the device
Description: Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
Study: NCT04436757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS program : Self-image and body representation
Description: The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~1. : Introduction~2. : Sensory approach workshop~3. : Self presentation and personal hygiene~4. : Organisation of well-being, planning and pictograms~5. : Becoming aware of my body, my envelope~6. : Presentation and self-esteem (photolanguage)~7. : Self-presentation in social interactions: Social codes~8. : My ideas and desires for change~9. : Places of well-being and clothing hygiene~10. : Vocational insertion devices~11. : Daring change : presence of a Socio-hairdresser~12. : The awakening of color : presence of a Socio-aesthetician~13. : Development of practice sheets and the network

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
Study: NCT02192489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.3 mg Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 0.6mg Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00588016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
Study: NCT03279744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radion™-pdt
Description: The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
Study: NCT03904914

Intervention type: OTHER
Intervention: TOCI
Description: TOCI staging evaluated
Study: NCT03367520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StayQuit
Description: StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
Study: NCT02992795

Intervention type: DEVICE
Intervention: BrainPulse
Description: JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.

Intervention type: DEVICE
Intervention: BrainPulse
Description: JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.

Intervention type: DEVICE
Intervention: BrainPulse
Description: JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.

Intervention type: DEVICE
Intervention: BrainPulse
Description: JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
Study: NCT04029402

Intervention type: OTHER
Intervention: RNA sequencing
Description: Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline

Intervention type: OTHER
Intervention: RNA sequencing
Description: Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
Study: NCT00951340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: 15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: 15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional processing and interpersonal therapy
Description: 15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening therapy
Description: 15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
Study: NCT00852852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Self-Report Assessment - Cancer (ESRA-C)
Description: The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
Study: NCT03490695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
Study: NCT01904994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POC (point-of-care) CD4+ (cluster of differentiation 4) Count
Description: Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated ART (antiretroviral therapy) Initiation
Description: Accelerated ART initiation for patients with POC CD4+ \< 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Care and Prevention Package
Description: Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cellular Appointment Reminders and Follow-Up
Description: SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
Study: NCT04653077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
Study: NCT01642576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss counselling
Description: Diet counselling with or without sports trainers, over 8 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss counselling
Description: Diet counselling with or without sports trainers, over 8 months